Key result
SGLT2 inhibitors emerge as highly effective treatment for diabetic cardiomyopathy and progression to HF.
Why the study?
The global prevalence of diabetes is increasing significantly, imposing substantial healthcare costs and poor health outcomes.
Diabetic cardiomyopathy is driven by metabolic and inflammatory changes, and SGLT2 inhibitors have emerged as a cornerstone therapy for mitigating heart failure risk in this population.
Answers are grounded in this paper and cite their sources.
Supports SGLT2 inhibitor consideration in diabetic cardiomyopathy; leaves open confirmation via dedicated RCTs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jorge et al. (2023) conducted a review in Diabetic Cardiomyopathy and Heart Failure. SGLT2 inhibitors was evaluated. Diabetic cardiomyopathy is characterized by cardiac stiffness and progression to heart failure, for which SGLT2 inhibitors have emerged as a highly effective treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: